Citizens & Northern Corp Decreases Stock Holdings in Eli Lilly and Company $LLY

Citizens & Northern Corp lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 15.8% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 282 shares of the company’s stock after selling 53 shares during the quarter. Citizens & Northern Corp’s holdings in Eli Lilly and Company were worth $220,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Jacobsen Capital Management boosted its holdings in shares of Eli Lilly and Company by 15.9% in the second quarter. Jacobsen Capital Management now owns 1,563 shares of the company’s stock valued at $1,218,000 after acquiring an additional 214 shares during the period. FNY Investment Advisers LLC raised its position in Eli Lilly and Company by 441.9% in the 2nd quarter. FNY Investment Advisers LLC now owns 1,138 shares of the company’s stock valued at $887,000 after purchasing an additional 928 shares during the last quarter. Chokshi & Queen Wealth Advisors Inc boosted its stake in Eli Lilly and Company by 9.5% during the 2nd quarter. Chokshi & Queen Wealth Advisors Inc now owns 1,036 shares of the company’s stock worth $807,000 after purchasing an additional 90 shares during the period. D.A. Davidson & CO. grew its position in Eli Lilly and Company by 5.0% during the 2nd quarter. D.A. Davidson & CO. now owns 46,111 shares of the company’s stock worth $35,945,000 after purchasing an additional 2,211 shares during the last quarter. Finally, Blume Capital Management Inc. grew its position in Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday, October 9th. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. HSBC boosted their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Guggenheim restated a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $938.61.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $799.85 on Wednesday. The firm has a market capitalization of $757.03 billion, a PE ratio of 52.28, a P/E/G ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The firm’s 50-day simple moving average is $759.77 and its 200 day simple moving average is $766.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business posted $3.92 earnings per share. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.